WayPoint Biomedical Holdings, Inc.
WayPoint Biomedical Holdings, Inc.
Your view on WYPH
Overview
What the company does, where it operates, and who runs it.
About WayPoint Biomedical Holdings, Inc.
- Industry
- Specialty Business Services
- Sector
- Industrials
- CEO
- Steven Fox
- Headquarters
- 17011 Beach Boulevard, Huntington Beach, CA, US
- Industry
- Specialty Business Services
- Sector
- Industrials
- CEO
- Steven Fox
- Headquarters
- 17011 Beach Boulevard, Huntington Beach, CA, US
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment.
It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests for cocaine and marijuana detection.
The company also develops and commercializes test kits for detection against possible explosive devices, biowarfare/bioterrorism agents, and the detection of weapons of mass destruction. In addition, it provides Frontline Explosive Test Kit for the detection of explosive residues.
The company offers its products to the over-the-counter diagnostic self-testing, the diagnostic point of care, and the homeland security and defense markets. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for WayPoint Biomedical Holdings, Inc., and the rating behind it. WYPH last traded at $0.0003; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for WayPoint Biomedical Holdings, Inc.. Starting points for WayPoint Biomedical Holdings, Inc.: beta -8.36 — an Specialty Business Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for WayPoint Biomedical Holdings, Inc.. WayPoint Biomedical Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for WayPoint Biomedical Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for WayPoint Biomedical Holdings, Inc.. WayPoint Biomedical Holdings, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
WayPoint Biomedical Holdings, Inc. valued side by side against its closest peers. WayPoint Biomedical Holdings, Inc. is measured against Specialty Business Services peers within the Industrials sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold WayPoint Biomedical Holdings, Inc., and how their positions are changing. At a $9,972 market value, institutional positions materially move WayPoint Biomedical Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by WayPoint Biomedical Holdings, Inc. executives and directors. Shares of WayPoint Biomedical Holdings, Inc. have traded between $0.0001 and $0.0021 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming WayPoint Biomedical Holdings, Inc.. WayPoint Biomedical Holdings, Inc. is a $9,972 Industrials company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming WayPoint Biomedical Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for WayPoint Biomedical Holdings, Inc.. Coverage tracks WayPoint Biomedical Holdings, Inc. within Specialty Business Services (Industrials). Press releases and market coverage, newest first.